Why biosimilars are an opportunity, but could also be a trap.


- Dec 15, 2020
Increasing customer engagement during COVID and after

- Dec 7, 2020
Reinventing business development in COVID-19 era: 5 strategies that works. Yes, we do it.

- Jul 28, 2020
The Second Wave of Biosimilars. How to find the best ones?

- Jul 28, 2020
13 recommendations to succeed when selecting 2nd wave biosimilars.

- Jul 20, 2020
Tenders and long term sustainability of biosimilars in Europe

- Jul 12, 2020
Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.

- Mar 23, 2020
Pros & Cons of today's best therapeutic option for Covid-19. What to do when we don't have time?

- Mar 21, 2020
Lessons taken from the coronavirus: redundant models instead of optimized can save us next time.

- Jan 24, 2020
At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.

- Dec 14, 2019
Is it true that biosimilars will increase the use of the molecule? Not always...

- Dec 12, 2019
4 frequent errors healthcare/pharma companies make when entering new markets

- Nov 16, 2019
8 (avoidable) mistakes made by pharmaceutical companies when entering European markets.

- Oct 17, 2019
Commercial strategies for biosimilars: Any sense to register several brands?

- Sep 2, 2019
Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

- Aug 11, 2019
Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

- Jul 17, 2019
Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

- Jun 28, 2019
Oncology products will represent more than 20% of the German drug market. Can the system support it?

- May 23, 2019
Parallel trading get 30% of branded products to Big Pharma in German market after patent expiration.

- May 8, 2019
Notes on the German generics and biosimilars market 2016-2018.